Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.22 (
cdc2
)
8,319
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Coordinate control of different classes of cyclins is fundamentally important for cell cycle regulation and tumor suppression, yet the underlying mechanisms are incompletely understood. Here we show that the
PARK2
tumor suppressor mediates this coordination. The
PARK2
E3 ubiquitin ligase coordinately controls the stability of both cyclin D and cyclin E. Analysis of approximately 5,000 tumor genomes shows that
PARK2
is a very frequently deleted gene in human cancer and uncovers a striking pattern of mutual exclusivity between
PARK2
deletion and amplification of CCND1, CCNE1 or CDK4-implicating these genes in a common pathway. Inactivation of
PARK2
results in the accumulation of cyclin D and acceleration of cell cycle progression. Furthermore,
PARK2
is a component of a new class of cullin-RING-containing ubiquitin ligases targeting both cyclin D and cyclin E for degradation. Thus,
PARK2
regulates cyclin-
CDK
complexes, as does the
CDK
inhibitor p16, but acts as a master regulator of the stability of G1/S cyclins.
...
PMID:Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. 2486 87